8.00
+0.35(+4.58%)
Currency In USD
| Previous Close | 7.65 |
| Open | 7.7 |
| Day High | 8.15 |
| Day Low | 7.7 |
| 52-Week High | 3,500.42 |
| 52-Week Low | 6.2 |
| Volume | 51,919 |
| Average Volume | 13,489 |
| Market Cap | 4.66M |
| PE | -0.66 |
| EPS | -12.12 |
| Moving Average 50 Days | 7.45 |
| Moving Average 200 Days | 156.71 |
| Change | 0.35 |
If you invested $1000 in Aclarion, Inc. (ACON) since IPO date, it would be worth $0.02 as of October 07, 2025 at a share price of $8. Whereas If you bought $1000 worth of Aclarion, Inc. (ACON) shares 2 years ago, it would be worth $0.14 as of October 07, 2025 at a share price of $8.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aclarion Honored as Finalist for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH
GlobeNewswire Inc.
9 hours ago
Company recognized for breakthrough Nociscan solution for chronic low back pain, one of the most widespread health challengesBROOMFIELD, Colo., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a
Aclarion Presents at LSI Europe ’25 Highlighting Nociscan Technology and Key Value Drivers
GlobeNewswire Inc.
Oct 01, 2025 11:17 AM GMT
BROOMFIELD, Colo., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help p
First Patients Enrolled at UHealth – University of Miami in Aclarion’s Pivotal CLARITY Trial
GlobeNewswire Inc.
Sep 25, 2025 10:00 AM GMT
Enrollment remains on track with internal interim results expected in Q2 2026Randomized study to evaluate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of lo